These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26780424)

  • 21. CPPD crystal deposition disease of the cervical spine: a common cause of acute neck pain encountered in the neurology department.
    Sekijima Y; Yoshida T; Ikeda S
    J Neurol Sci; 2010 Sep; 296(1-2):79-82. PubMed ID: 20646716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of alkaline phosphatase by cysteine: implications for calcium pyrophosphate dihydrate crystal deposition disease.
    So PP; Tsui FW; Vieth R; Tupy JH; Pritzker KP
    J Rheumatol; 2007 Jun; 34(6):1313-22. PubMed ID: 17516619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating CPPD crystal deposition, an important disease of aging.
    Bonafede RP
    Geriatrics; 1988 Nov; 43(11):59-64, 68. PubMed ID: 2846412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenesis of calcium pyrophosphate deposition disease.
    Williams CJ; Rosenthal AK
    Best Pract Res Clin Rheumatol; 2021 Dec; 35(4):101718. PubMed ID: 34696986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of alkaline phosphatase: implications for calcium pyrophosphate dihydrate crystal dissolution and other alkaline phosphatase functions.
    Shinozaki T; Pritzker KP
    J Rheumatol; 1996 Apr; 23(4):677-83. PubMed ID: 8730126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hip Involvement in Patients With Calcium Pyrophosphate Deposition Disease: Potential and Limits of Musculoskeletal Ultrasound.
    Di Matteo A; Filippucci E; Cipolletta E; Musca A; Carotti M; Mashadi Mirza R; Jesus D; Martire V; Pierucci D; Di Carlo M; Salaffi F; Grassi W
    Arthritis Care Res (Hoboken); 2019 Dec; 71(12):1671-1677. PubMed ID: 30474924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrasound findings of calcium pyrophosphate deposition disease at metacarpophalangeal joints.
    Cipolletta E; Di Matteo A; Smerilli G; Di Carlo M; Di Battista J; Abhishek A; Grassi W; Filippucci E
    Rheumatology (Oxford); 2022 Oct; 61(10):3997-4005. PubMed ID: 35104308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium crystal deposition diseases: update on pathogenesis and manifestations.
    Molloy ES; McCarthy GM
    Rheum Dis Clin North Am; 2006 May; 32(2):383-400, vii. PubMed ID: 16716885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prevalence of and factors related to calcium pyrophosphate dihydrate crystal deposition in the knee joint.
    Ryu K; Iriuchishima T; Oshida M; Kato Y; Saito A; Imada M; Aizawa S; Tokuhashi Y; Ryu J
    Osteoarthritis Cartilage; 2014 Jul; 22(7):975-9. PubMed ID: 24814686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histochemical localization of calcium with potassium pyroantimonate in the articular tissues in calcium pyrophosphate dihydrate crystal deposition disease.
    Ohira T; Ishikawa K
    Clin Orthop Relat Res; 1991 Mar; (264):286-94. PubMed ID: 1705190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical aspects of calcium pyrophosphate dihydrate crystal deposition.
    Doherty M; Dieppe P
    Rheum Dis Clin North Am; 1988 Aug; 14(2):395-414. PubMed ID: 2845493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease.
    Altomare A; Corrado A; Maruotti N; Cici D; Cantatore FP
    Mol Biol Rep; 2021 May; 48(5):4789-4796. PubMed ID: 34075537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crystal arthritis: contemporary approaches to diseases of antiquity.
    Lillicrap M
    Clin Med (Lond); 2007; 7(1):60-4. PubMed ID: 17348578
    [No Abstract]   [Full Text] [Related]  

  • 34. Application of scanning and transmission electron microscopy, x-ray energy spectroscopy, and x-ray diffraction to calcium pyrophosphate crystal formation in vitro.
    Omar SA; Cheng PT; Nyburg SC; Pritzker KP
    Scan Electron Microsc; 1979; (2):745-9. PubMed ID: 230578
    [No Abstract]   [Full Text] [Related]  

  • 35. Idiopathic widespread calcium pyrophosphate dihydrate crystal deposition disease in a young patient.
    Hayashi M; Matsunaga T; Tanikawa H
    Skeletal Radiol; 2002 Apr; 31(4):246-50. PubMed ID: 11904695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyrophosphate, phosphate ion interaction: effects on calcium pyrophosphate and calcium hydroxyapatite crystal formation in aqueous solutions.
    Cheng PT; Pritzker KP
    J Rheumatol; 1983 Oct; 10(5):769-77. PubMed ID: 6315937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group.
    Cai K; Fuller A; Zhang Y; Hensey O; Grossberg D; Christensen R; Shea B; Singh JA; McCarthy GM; Rosenthal AK; Filippou G; Taylor WJ; Diaz-Torne C; Stamp LK; Edwards NL; Pascart T; Becce F; Nielsen SM; Tugwell P; Beaton D; Abhishek A; Tedeschi SK; Dalbeth N
    Semin Arthritis Rheum; 2021 Aug; 51(4):946-950. PubMed ID: 34140183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Geographic distribution of calcium pyrophosphate (CPPD) deposition disease in pre-Columbian North America: independent validation of CPPD criteria.
    Rothschild BM; Woods RJ
    Clin Exp Rheumatol; 1993; 11(3):315-8. PubMed ID: 8353987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chondrocalcinosis and calcium pyrophosphate (CPP) crystal deposition disease in 2010].
    Guerne PA
    Rev Med Suisse; 2010 Mar; 6(240):555-6, 558, 560-1. PubMed ID: 20408460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal deposition disease in the elderly.
    Doherty M; Dieppe P
    Clin Rheum Dis; 1986 Apr; 12(1):97-116. PubMed ID: 3013494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.